Gabriella Ngang, of Farmington Hills, is one of three in Michigan to take part in a clinical trial of a new sickle cell ...

Beam Therapeutics Inc. (NASDAQ:BEAM) is one of the 13 Best Pharma Stocks to Buy According to Wall Street Analysts. On July 1, ...

Sickle cell disease is one of the most common genetic blood disorders in the world. It affects millions globally, with the highest burden seen in people of African, Caribbean, Middle Eastern, and ...

"Vertex reports long-term results for Casgevy in sickle cell and thalassaemia" was originally created and published by ...

As a result of being a caregiver for her cousin, columnist Sylvia Amuta says she's now more caring, compassionate, and kind to others.

Sickle cell disease affects about 100,000 people in the U.S., and 90% of patients are Black, according to NIH.

Vertex Pharmaceuticals unveiled impressive long-term results for its CRISPR/Cas9 gene therapy, PrCASGEVY, at the EHA Congress ...

Higher pain scores upon discharge from the emergency department may predict hospitalization in adolescents with SCD, a study ...

Beam Therapeutics Inc. (NASDAQ:BEAM) ranks among the best CRISPR stocks to buy. On June 13, Beam Therapeutics Inc.

A researcher at Duke University, speaks out after her NIH grant for sickle cell research was terminated. The $750,000 funding ...

In a sharply divided political climate, San Rocco Therapeutics (SRT) has done what few thought possible—earned support from both the highest levels of Washington and from those who distrust it.

A doctor says she’s scrambling to figure out how she’ll continue her work helping sickle cell disease patients after the ...